These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. An open label study to establish dosing recommendations for nabumetone in juvenile rheumatoid arthritis. Goodman S; Howard P; Haig A; Flavin S; Macdonald B J Rheumatol; 2003 Apr; 30(4):829-31. PubMed ID: 12672207 [TBL] [Abstract][Full Text] [Related]
12. Pseudoporphyria induced by propionic acid derivatives. Al-Khenaizan S; Schechter JF; Sasseville D J Cutan Med Surg; 1999 Jan; 3(3):162-6. PubMed ID: 10082597 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of nabumetone in patients with rheumatic diseases. Results of an outpatient study involving 8,865 patients. Stroehmann I; Giersch KH; Zeidler H; Münzel P Drugs; 1990; 40 Suppl 5():50-2. PubMed ID: 2081493 [No Abstract] [Full Text] [Related]
14. Pseudoporphyria from nonsteroidal antiinflammatory drugs. Taylor BJ; Duffill MB N Z Med J; 1987 May; 100(824):322-3. PubMed ID: 3451093 [TBL] [Abstract][Full Text] [Related]
18. Pulmonary fibrosis associated with nabumetone. Morice A; Atherton A; Gleeson F; Stewart S Postgrad Med J; 1991 Nov; 67(793):1021-2. PubMed ID: 1775411 [TBL] [Abstract][Full Text] [Related]
19. Nabumetone, an effective anti-inflammatory agent, lacks gastrointestinal irritancy in the rat when dosed orally for one month: comparison with tiaprofenic acid and etodolac. Melarange R; Gentry C; Blower PR; Toseland CD; Spangler R Eur J Rheumatol Inflamm; 1994; 14(2):15-22. PubMed ID: 7744129 [TBL] [Abstract][Full Text] [Related]